Sold as Centrax. Every FDA application for this active ingredient: 2 branded and 2 generic.
As of Nov 13, 2026, FDA lists 4 applications for Prazepam (sold as Centrax), first approved Nov 30, 1979, with 0 new uses approved and 0 published complete response letters.
| Nov 30, 1979 | CentraxNDA 18144 · New dosage form | Parke Davis | 7 | Discontinued |
| — | PrazepamANDA 70427 | Usl Pharma | 0 | Discontinued |
| — | PrazepamANDA 70428 | Usl Pharma | 0 | Discontinued |
| — | CentraxNDA 17415 | Parke Davis | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Parke Davis